Evaluation of Cyfra 21.1 as a Tumor Marker in Lung Cancer
Author Information
Author(s): A. van der Gaast, C.H.H. Schoenmakers, T.C. Kok, B.G. Blijenberg, F. Cornillie, T.A.W. Splinter
Primary Institution: University Hospital Rotterdam-Dijkzigt
Hypothesis
The study aims to evaluate the sensitivity of the Cyfra 21.1 tumor marker in patients with non-small-cell lung cancer (NSCLC).
Conclusion
Cyfra 21.1 is a useful serum marker for monitoring disease in patients with NSCLC, particularly those with squamous cell carcinoma during chemotherapy.
Supporting Evidence
- The sensitivity of Cyfra 21.1 was found to be 40%, similar to CEA and TPA but higher than SCC.
- Cyfra 21.1 showed a concordance of 74% with clinical evaluations for monitoring treatment response.
- Patients with squamous cell carcinoma had a higher sensitivity for Cyfra 21.1 compared to other histological types.
Takeaway
Researchers tested a new blood test called Cyfra 21.1 to see if it helps doctors track lung cancer better, especially in patients with a specific type of lung cancer.
Methodology
The study involved collecting serum samples from 212 patients with NSCLC and comparing the sensitivity of Cyfra 21.1 with other tumor markers.
Limitations
The sensitivity of Cyfra 21.1 is too low for screening purposes, and the study's findings may not apply to all types of lung cancer.
Participant Demographics
{"total_patients":212,"male":172,"female":40,"median_age":59,"stage_distribution":{"stage_I":5,"stage_II":2,"stage_IIIa":59,"stage_IIIb":37,"stage_IV":109},"histology_distribution":{"adenocarcinoma":65,"squamous_cell_carcinoma":80,"large_cell_undifferentiated":67}}
Statistical Information
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website